Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
359 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ulcerative Colitis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Ulcerative Colitis - Pipeline Review, H1 2015', provides an overview of the Ulcerative Colitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Ulcerative Colitis Overview 11 Therapeutics Development 12 Pipeline Products for Ulcerative Colitis - Overview 12 Pipeline Products for Ulcerative Colitis - Comparative Analysis 13 Ulcerative Colitis - Therapeutics under Development by Companies 14 Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 21 Ulcerative Colitis - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Ulcerative Colitis - Products under Development by Companies 26 Ulcerative Colitis - Products under Investigation by Universities/Institutes 33 Ulcerative Colitis - Companies Involved in Therapeutics Development 34 Ajinomoto Pharmaceuticals Co., Ltd. 34 AlphaMab Co., Ltd 35 Altheus Therapeutics, Inc. 36 Am-Pharma B.V. 37 Amgen Inc. 38 Astellas Pharma Inc. 39 AstraZeneca PLC 40 Athersys, Inc. 41 Atlantic Healthcare plc 42 Avaxia Biologics, Inc. 43 Biocon Limited 44 BioLineRx, Ltd. 45 Bristol-Myers Squibb Company 46 Celgene Corporation 47 Cellceutix Corporation 48 Celltrion, Inc. 49 ChemoCentryx, Inc. 50 ChironWells GmbH 51 Cosmo Pharmaceuticals S.p.A 52 Dr. Falk Pharma GmbH 53 Drais Pharmaceuticals, Inc. 54 Effimune SAS 55 Emergent BioSolutions Inc. 56 Enceladus Pharmaceuticals BV 57 Epirus Biopharmaceuticals, Inc. 58 Euroscreen S.A. 59 Farmacija d.o.o. Tuzla 60 Flexion Therapeutics, Inc. 61 Galapagos NV 62 Genentech, Inc. 63 Genfit SA 64 Genor BioPharma Co., Ltd. 65 Gilead Sciences, Inc. 66 GT Biologics Limited 67 GW Pharmaceuticals plc 68 iCo Therapeutics Inc. 69 InDex Pharmaceuticals AB 70 INOXIA Lifesciences GmbH 71 Invion Limited 72 Johnson & Johnson 73 Kaken Pharmaceutical Co., Ltd. 74 LIPID THERAPEUTICS GmbH 75 LTT Bio-Pharma Co., Ltd. 76 Mabion SA 77 Medestea Research & Production S.p.A. 78 Morphotek, Inc. 79 Nogra Pharma Limited 80 Oncobiologics, Inc. 81 Pfizer Inc. 82 Pluristem Therapeutics Inc. 83 ProtAb Ltd 84 Qu Biologics Inc. 85 Receptos, Inc. 86 Sandoz Inc. 87 Sanofi 88 Sigmoid Pharma Limited 89 Stelic Institute & Co. 90 sterna biologicals Gmbh & Co KG 91 Synergy Pharmaceuticals, Inc. 92 Takeda Pharmaceutical Company Limited 93 TiGenix NV 94 Tillotts Pharma AG 95 Trino Therapeutics Ltd 96 Vascular Biogenics Ltd. 97 Ventria Bioscience 98 Zyngenia, Inc. 99 Ulcerative Colitis - Therapeutics Assessment 100 Assessment by Monotherapy Products 100 Assessment by Combination Products 101 Assessment by Target 102 Assessment by Mechanism of Action 106 Assessment by Route of Administration 109 Assessment by Molecule Type 111 Drug Profiles 113 (mesalamine + N-acetylcysteine) - Drug Profile 113 (metenkefalin + tridecactide) - Drug Profile 115 AB-0045 - Drug Profile 116 abrilumab - Drug Profile 117 ABS-11 - Drug Profile 119 adalimumab biosimilar - Drug Profile 120 adalimumab biosimilar - Drug Profile 122 adalimumab biosimilar - Drug Profile 123 adalimumab biosimilar - Drug Profile 124 adalimumab biosimilar - Drug Profile 125 adalimumab biosimilar - Drug Profile 126 adalimumab biosimilar - Drug Profile 127 adalimumab biosimilar - Drug Profile 128 AJM-300 - Drug Profile 129 alicaforsen sodium - Drug Profile 131 Anatabine - Drug Profile 132 apremilast - Drug Profile 133 ASP-3291 - Drug Profile 136 AVX-470 - Drug Profile 137 AW/EPO-002 - Drug Profile 138 AW/EPO-003 - Drug Profile 139 AW/EPOPD-01 - Drug Profile 140 AW/EPOPD-02 - Drug Profile 141 AW/EPOPD-06 - Drug Profile 142 bertilimumab - Drug Profile 143 BL-7040 - Drug Profile 145 BLI-1006 - Drug Profile 148 brilacidin - Drug Profile 149 budesonide - Drug Profile 151 budesonide ER - Drug Profile 154 budesonide ER - Drug Profile 156 CCX-507 - Drug Profile 157 Cell Therapy for Ulcerative Colitis and Inflammatory Bowel Disease - Drug Profile 158 CNDO-201 - Drug Profile 159 Cx-602 - Drug Profile 161 cyclosporine CR - Drug Profile 162 DIMS-0150 - Drug Profile 163 Drugs for Ulcerative Colitis - Drug Profile 165 eldelumab - Drug Profile 166 enalaprilat - Drug Profile 168 ES-210 - Drug Profile 169 ESN-282 - Drug Profile 170 etrolizumab - Drug Profile 171 FX-003 - Drug Profile 173 GED-0507 - Drug Profile 174 GFT-505 - Drug Profile 175 GLPG-0974 - Drug Profile 178 GLPG-1205 - Drug Profile 179 GS-5745 - Drug Profile 180 GWP-42003 - Drug Profile 181 hyaluronate sodium - Drug Profile 183 IAC VITA - Drug Profile 184 infliximab - Drug Profile 186 infliximab biosimilar - Drug Profile 188 infliximab biosimilar - Drug Profile 190 infliximab biosimilar - Drug Profile 191 infliximab biosimilar - Drug Profile 192 INV-103 - Drug Profile 193 INV-88 - Drug Profile 195 KAG-308 - Drug Profile 196 KANAb-071 - Drug Profile 197 Leukothera - Drug Profile 198 Low Molecular Weight Heparin - Drug Profile 199 LT-0011 - Drug Profile 200 LT-02 - Drug Profile 201 MD-707 - Drug Profile 202 mesalamine - Drug Profile 203 mesalamine - Drug Profile 204 mesalamine CR - Drug Profile 205 mesalamine ER - Drug Profile 206 Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease - Drug Profile 208 Monoclonal Antibodies to Inhibit TNFR25 for Gastrointestinal Disorders and Asthma - Drug Profile 210 Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis, Arthritis and Inflammatory Disease - Drug Profile 211 Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 212 MultiStem - Drug Profile 214 naltrexone - Drug Profile 217 Nanocort - Drug Profile 218 peficitinib - Drug Profile 220 Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn's Disease - Drug Profile 222 PF-00547659 - Drug Profile 223 PH-44 - Drug Profile 225 PH-46A - Drug Profile 226 PH-5 - Drug Profile 227 Prozumab - Drug Profile 228 QBECO - Drug Profile 229 Recombinant Human Alkaline Phosphatase - Drug Profile 231 Rosburix - Drug Profile 233 RPC-1063 - Drug Profile 234 SAR-252067 - Drug Profile 236 SB-012 - Drug Profile 237 SD-010 - Drug Profile 238 Small Molecule for Ulcerative Colitis and Inflammation - Drug Profile 239 Small Molecule to Agonize OP3 Receptor for Crohn's Disease and Ulcerative Colitis - Drug Profile 240 Small Molecules for Gastrointestinal Disorders - Drug Profile 241 Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile 242 Small Molecules to Target IL-13 for Ulcerative Colitis - Drug Profile 243 SP-333 - Drug Profile 244 Stem Cell Therapy for Inflammatory Bowel Disease - Drug Profile 245 STNM-01 - Drug Profile 246 TAK-114 - Drug Profile 247 tofacitinib - Drug Profile 249 TP-10 - Drug Profile 253 VB-201 - Drug Profile 254 VEDA-1209 - Drug Profile 256 vedolizumab - Drug Profile 257 VEN-120 - Drug Profile 259 Ulcerative Colitis - Recent Pipeline Updates 260 Ulcerative Colitis - Dormant Projects 337 Ulcerative Colitis - Discontinued Products 340 Ulcerative Colitis - Product Development Milestones 342 Featured News & Press Releases 342 Appendix 350 Methodology 350 Coverage 350 Secondary Research 350 Primary Research 350 Expert Panel Validation 350 Contact Us 351 Disclaimer 351
List of Tables Number of Products under Development for Ulcerative Colitis, H1 2015 20 Number of Products under Development for Ulcerative Colitis - Comparative Analysis, H1 2015 21 Number of Products under Development by Companies, H1 2015 23 Number of Products under Development by Companies, H1 2015 (Contd..1) 24 Number of Products under Development by Companies, H1 2015 (Contd..2) 25 Number of Products under Development by Companies, H1 2015 (Contd..3) 26 Number of Products under Development by Companies, H1 2015 (Contd..4) 27 Number of Products under Development by Companies, H1 2015 (Contd..5) 28 Number of Products under Investigation by Universities/Institutes, H1 2015 29 Comparative Analysis by Late Stage Development, H1 2015 30 Comparative Analysis by Clinical Stage Development, H1 2015 31 Comparative Analysis by Early Stage Development, H1 2015 32 Comparative Analysis by Unknown Stage Development, H1 2015 33 Products under Development by Companies, H1 2015 34 Products under Development by Companies, H1 2015 (Contd..1) 35 Products under Development by Companies, H1 2015 (Contd..2) 36 Products under Development by Companies, H1 2015 (Contd..3) 37 Products under Development by Companies, H1 2015 (Contd..4) 38 Products under Development by Companies, H1 2015 (Contd..5) 39 Products under Development by Companies, H1 2015 (Contd..6) 40 Products under Investigation by Universities/Institutes, H1 2015 41 Ulcerative Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2015 42 Ulcerative Colitis - Pipeline by AlphaMab Co., Ltd, H1 2015 43 Ulcerative Colitis - Pipeline by Altheus Therapeutics, Inc., H1 2015 44 Ulcerative Colitis - Pipeline by Am-Pharma B.V., H1 2015 45 Ulcerative Colitis - Pipeline by Amgen Inc., H1 2015 46 Ulcerative Colitis - Pipeline by Astellas Pharma Inc., H1 2015 47 Ulcerative Colitis - Pipeline by AstraZeneca PLC, H1 2015 48 Ulcerative Colitis - Pipeline by Athersys, Inc., H1 2015 49 Ulcerative Colitis - Pipeline by Atlantic Healthcare plc, H1 2015 50 Ulcerative Colitis - Pipeline by Avaxia Biologics, Inc., H1 2015 51 Ulcerative Colitis - Pipeline by Biocon Limited, H1 2015 52 Ulcerative Colitis - Pipeline by BioLineRx, Ltd., H1 2015 53 Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2015 54 Ulcerative Colitis - Pipeline by Celgene Corporation, H1 2015 55 Ulcerative Colitis - Pipeline by Cellceutix Corporation, H1 2015 56 Ulcerative Colitis - Pipeline by Celltrion, Inc., H1 2015 57 Ulcerative Colitis - Pipeline by ChemoCentryx, Inc., H1 2015 58 Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2015 59 Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 60 Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2015 61 Ulcerative Colitis - Pipeline by Drais Pharmaceuticals, Inc., H1 2015 62 Ulcerative Colitis - Pipeline by Effimune SAS, H1 2015 63 Ulcerative Colitis - Pipeline by Emergent BioSolutions Inc., H1 2015 64 Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2015 65 Ulcerative Colitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 66 Ulcerative Colitis - Pipeline by Euroscreen S.A., H1 2015 67 Ulcerative Colitis - Pipeline by Farmacija d.o.o. Tuzla, H1 2015 68 Ulcerative Colitis - Pipeline by Flexion Therapeutics, Inc., H1 2015 69 Ulcerative Colitis - Pipeline by Galapagos NV, H1 2015 70 Ulcerative Colitis - Pipeline by Genentech, Inc., H1 2015 71 Ulcerative Colitis - Pipeline by Genfit SA, H1 2015 72 Ulcerative Colitis - Pipeline by Genor BioPharma Co., Ltd., H1 2015 73 Ulcerative Colitis - Pipeline by Gilead Sciences, Inc., H1 2015 74 Ulcerative Colitis - Pipeline by GT Biologics Limited, H1 2015 75 Ulcerative Colitis - Pipeline by GW Pharmaceuticals plc, H1 2015 76 Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2015 77 Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H1 2015 78 Ulcerative Colitis - Pipeline by INOXIA Lifesciences GmbH, H1 2015 79 Ulcerative Colitis - Pipeline by Invion Limited, H1 2015 80 Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2015 81 Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015 82 Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2015 83 Ulcerative Colitis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 84 Ulcerative Colitis - Pipeline by Mabion SA, H1 2015 85 Ulcerative Colitis - Pipeline by Medestea Research & Production S.p.A., H1 2015 86 Ulcerative Colitis - Pipeline by Morphotek, Inc., H1 2015 87 Ulcerative Colitis - Pipeline by Nogra Pharma Limited, H1 2015 88 Ulcerative Colitis - Pipeline by Oncobiologics, Inc., H1 2015 89 Ulcerative Colitis - Pipeline by Pfizer Inc., H1 2015 90 Ulcerative Colitis - Pipeline by Pluristem Therapeutics Inc., H1 2015 91 Ulcerative Colitis - Pipeline by ProtAb Ltd, H1 2015 92 Ulcerative Colitis - Pipeline by Qu Biologics Inc., H1 2015 93 Ulcerative Colitis - Pipeline by Receptos, Inc., H1 2015 94 Ulcerative Colitis - Pipeline by Sandoz Inc., H1 2015 95 Ulcerative Colitis - Pipeline by Sanofi, H1 2015 96 Ulcerative Colitis - Pipeline by Sigmoid Pharma Limited, H1 2015 97 Ulcerative Colitis - Pipeline by Stelic Institute & Co., H1 2015 98 Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 99 Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 100 Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 101 Ulcerative Colitis - Pipeline by TiGenix NV, H1 2015 102 Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H1 2015 103 Ulcerative Colitis - Pipeline by Trino Therapeutics Ltd, H1 2015 104 Ulcerative Colitis - Pipeline by Vascular Biogenics Ltd., H1 2015 105 Ulcerative Colitis - Pipeline by Ventria Bioscience, H1 2015 106 Ulcerative Colitis - Pipeline by Zyngenia, Inc., H1 2015 107 Assessment by Monotherapy Products, H1 2015 108 Assessment by Combination Products, H1 2015 109 Number of Products by Stage and Target, H1 2015 111 Number of Products by Stage and Mechanism of Action, H1 2015 115 Number of Products by Stage and Route of Administration, H1 2015 118 Number of Products by Stage and Molecule Type, H1 2015 120 Ulcerative Colitis Therapeutics - Recent Pipeline Updates, H1 2015 268 Ulcerative Colitis - Dormant Projects, H1 2015 345 Ulcerative Colitis - Discontinued Products, H1 2015 348 Ulcerative Colitis - Discontinued Products (Contd..1), H1 2015 349
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
